Movement Alert｜Pharmaron Rises 5.72% in Regular Trading, CXO Sector Rallies on Strong Q1 Data and Innovation Drug Financing Surge

Market Focus06-29

On June 29, Pharmaron (03759.HK) rose 5.72% in regular trading, trading at HK$18.3/share, with turnover of HK$226 million. The gain came amid a broad rally across the CXO (pharmaceutical outsourcing) sector.

On the news front, research data showed that 22 listed CXO companies collectively achieved Q1 revenue, net profit, and adjusted net profit growth of 18.6%, 21.9%, and 63.5% year-over-year respectively, confirming sequential quarterly improvement. Meanwhile, China's innovative drug primary market financing totaled US$2.59 billion in Q1, surging 128.6% year-over-year, while China-related deal value reached US$61.4 billion, significantly outpacing overseas transactions. Institutions noted that as China's share in global drug R&D innovation rises, the supporting CXO supply chain stands to benefit further.

Pharmaron itself reported Q1 revenue of RMB 3.578 billion, up 15.48% year-over-year, with its small-molecule CDMO segment seeing new orders jump over 50%. The BIO2026 conference held June 22-25 also highlighted Chinese CXO firms' efficiency advantages, reinforcing positive sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144260281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144260281","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pharmaron Rises 5.72% in Regular Trading, CXO Sector Rallies on Strong Q1 Data and Innovation Drug Financing Surge","media":"Market Focus","content":"<p><p>On June 29, Pharmaron (03759.HK) rose 5.72% in regular trading, trading at HK$18.3/share, with turnover of HK$226 million. The gain came amid a broad rally across the CXO (pharmaceutical outsourcing) sector.</p><p>On the news front, research data showed that 22 listed CXO companies collectively achieved Q1 revenue, net profit, and adjusted net profit growth of 18.6%, 21.9%, and 63.5% year-over-year respectively, confirming sequential quarterly improvement. Meanwhile, China's innovative drug primary market financing totaled US$2.59 billion in Q1, surging 128.6% year-over-year, while China-related deal value reached US$61.4 billion, significantly outpacing overseas transactions. Institutions noted that as China's share in global drug R&D innovation rises, the supporting CXO supply chain stands to benefit further.</p><p>Pharmaron itself reported Q1 revenue of RMB 3.578 billion, up 15.48% year-over-year, with its small-molecule CDMO segment seeing new orders jump over 50%. The BIO2026 conference held June 22-25 also highlighted Chinese CXO firms' efficiency advantages, reinforcing positive sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pharmaron Rises 5.72% in Regular Trading, CXO Sector Rallies on Strong Q1 Data and Innovation Drug Financing Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pharmaron Rises 5.72% in Regular Trading, CXO Sector Rallies on Strong Q1 Data and Innovation Drug Financing Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, Pharmaron (03759.HK) rose 5.72% in regular trading, trading at HK$18.3/share, with turnover of HK$226 million. The gain came amid a broad rally across the CXO (pharmaceutical outsourcing) sector.</p><p>On the news front, research data showed that 22 listed CXO companies collectively achieved Q1 revenue, net profit, and adjusted net profit growth of 18.6%, 21.9%, and 63.5% year-over-year respectively, confirming sequential quarterly improvement. Meanwhile, China's innovative drug primary market financing totaled US$2.59 billion in Q1, surging 128.6% year-over-year, while China-related deal value reached US$61.4 billion, significantly outpacing overseas transactions. Institutions noted that as China's share in global drug R&D innovation rises, the supporting CXO supply chain stands to benefit further.</p><p>Pharmaron itself reported Q1 revenue of RMB 3.578 billion, up 15.48% year-over-year, with its small-molecule CDMO segment seeing new orders jump over 50%. The BIO2026 conference held June 22-25 also highlighted Chinese CXO firms' efficiency advantages, reinforcing positive sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1144260281","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144260281","pubTimestamp":1782713632,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, Pharmaron (03759.HK) rose 5.72% in regular trading, trading at HK$18.3/share, with turnover of HK$226 million. The gain came amid a broad rally across the CXO (pharmaceutical outsourcing)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"动向提示|康龙化成常规交易涨5.72%，CXO板块因Q1数据强劲和创新药融资激增而反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On June 29, Pharmaron (03759.HK) rose 5.72% in regular trading, trading at HK$18.3/share, with turnover of HK$226 million. The gain came amid a broad rally across the CXO (pharmaceutical outsourcing) sector.On the news front, research data showed that 22 listed CXO companies collectively achieved Q1 revenue, net profit, and adjusted net profit growth of 18.6%, 21.9%, and 63.5% year-over-year respectively, confirming sequential quarterly improvement. Meanwhile, China's innovative drug primary market financing totaled US$2.59 billion in Q1, surging 128.6% year-over-year, while China-related deal value reached US$61.4 billion, significantly outpacing overseas transactions. Institutions noted that as China's share in global drug R&D innovation rises, the supporting CXO supply chain stands to benefit further.Pharmaron itself reported Q1 revenue of RMB 3.578 billion, up 15.48% year-over-year, with its small-molecule CDMO segment seeing new orders jump over 50%. The BIO2026 conference held June 22-25 also highlighted Chinese CXO firms' efficiency advantages, reinforcing positive sector sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144260281","isCrawlerRequest":true}